NAV
₹379.8786
as of 30 Sept 2026
Expense Ratio
1.33%
Lumpsum returns (CAGR)
- 1Y
- +18.26%
- 3Y
- +22.68%
- 5Y
- +15.39%
- Since Inception
- +16.30%
SIP returns (XIRR)
- 1Y
- +22.94%
- 3Y
- +18.23%
- 5Y
- +20.59%
- Since Inception
- +13.48%
Performance Comparison
Sectoral allocation
as of 31 Aug 2026- Pharmaceuticals & Biotechnology67.86%
- Healthcare Services23.98%
- Chemicals & Petrochemicals1.42%
- Healthcare Equipment & Supplies0.98%
Each sector links to the mutual funds most exposed to it.
Thinking about UTI Healthcare Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with UTI Healthcare Fund - Regular Plan - Growth Option
- 1Sun Pharmaceuticals Industries8.25%
- 2Divis Laboratories Ltd.6.21%
- 3Ajanta Pharma Ltd.4.74%
- 4Gland Pharma Ltd.3.70%
- 5Dr Reddys Laboratories Ltd.3.62%
- 6Alkem Laboratories Ltd3.29%
- 7Apollo Hospitals Enterprise Lt3.27%
- 8Max Healthcare Institute Ltd3.10%
- 9Lupin Ltd.3.09%
- 10Caplin Point Laboratories Ltd3.05%
What this fund does
UTI Healthcare Fund · Direct · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
UTI Healthcare Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by UTI Mutual Fund. The fund has been operational for over 13 years. The current expense ratio is 1.33%.